emricasan Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Emricasan is a potential drug invented in 1998 by Idun Pharmaceuticals. The drug was acquired by Pfizer in 2005 and then sold to Conatus Pharmaceuticals in 2010. Conatus in turn licensed emricasan to Novartis in 2017 for exclusive development and commercialization.   Wikipedia

Chemistry

  • SMILES: C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F
  • InChIKey: SCVHJVCATBPIHN-SJCJKPOMSA-N
  • Mol. Mass: 569.51
  • ALogP: 2.59
  • ChEMBL Molecule:
    emricasan  
More Chemistry

Pharmacology

Alternative names

3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid | emricasan | idn6556 | idn 6556 | idn-6556 | pf03491390 | pf 03491390 | pf-03491390

Organizations (7)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Carcinoma, Hepatocellular (Phase 2)

Cholestasis (Phase 2)

COVID-19 (Phase 1)

Diabetes Mellitus (Phase 1/Phase 2)

Digestive System Diseases (Phase 1)

Fibrosis (Phase 2)

Hepatitis (Phase 2)

Hepatitis, Alcoholic (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hypertension, Portal (Phase 2)

Kidney Diseases (Phase 1)

Kidney Failure, Chronic (Phase 1)

Liver Cirrhosis (Phase 2)

Liver Diseases (Phase 2)

Liver Failure (Phase 2)

Liver Failure, Acute (Phase 2)

Liver Transplantation (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Renal Insufficiency (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 17
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue